Tradestie Institutional Equity Comparison Engine

PTGX vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PTGX Overall Edge

PTGX Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Protagonist Therapeutics, Inc (PTGX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, PTGX trades at 36.9x Forward P/E with 58.6% operating margin (+5723.6% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, PTGX sits in CONSOLIDATION (3rd %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
PTGX 36.9x vs CRSP 23.4x Fwd P/E
Growth & Margin Winner PTGX
Op Margin 58.6% vs -2058.6% ยท YoY +5723.6% vs +1325.1%
Momentum & Technical Winner PTGX
1Y +50.6% vs -20.5% ยท 52W Pos 58% vs 1%
Options & Structure Winner PTGX
CONSOLIDATION (3rd %ile IV) vs BREAKDOWN (52nd %ile IV)
PTGX NASDAQ
Protagonist Therapeutics, Inc
Pharmaceutical Preparations
$125.40
-4.24% 1D
Market Cap $8.7B
1M Return -2.6%
1Y Return +50.65%
Forward P/E 36.9x
Unified AI Score
32.6 / 100 SELL
Tech 17.0 Fund 44.0 Flow 67.0 Mom 60.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PTGX +50.65% CRSP -20.54% Spread: +71.19 pp (PTGX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PTGX Revenue CRSP Revenue PTGX Op. Margin CRSP Op. Margin Margin Edge
FY2018 $30M $0M -136.7% -5087.8% PTGX
FY2019 $0M $290M -34857.6% 16.1% CRSP
FY2020 $30M $0M -225.4% -49295.5% PTGX
FY2021 $30M $910M -460.0% 40.8% CRSP
FY2022 $30M $0M -494.2% -56190.4% PTGX
FY2023 $60M $370M -156.1% -60.0% CRSP
FY2024 $430M $40M 58.2% -1250.4% PTGX
FY2025 $50M $0M -343.6% -18933.6% PTGX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PTGX (7) vs CRSP (3)
Institutional Metric PTGX CRSP Criterion Row Winner
Market Capitalization Scale $8.7B $4.1B Larger Scale PTGX
Trailing P/E Ratio Valuation 28.1x 23.4x Lower Multiple CRSP
Forward P/E Ratio Valuation 36.9x 23.4x Lower Multiple CRSP
Revenue Growth (YoY) Growth +5723.6% +1325.1% Higher Growth PTGX
Operating Margin (TTM) Profitability 58.6% -2058.6% Higher Margin PTGX
Net Profit Margin Profitability 62.0% 0.0% Higher Margin PTGX
Return on Equity (ROE) Capital Efficiency 39.6% -25.6% Higher ROE PTGX
52-Week Range Position Momentum 58% ($77โ€“$161) 1% ($40โ€“$63) Stronger Trend PTGX
Beta / 30D Volatility Risk Regime 1.02ฮฒ ยท 35% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk PTGX
Unified Institutional Score Composite Signal 32.6 / 100 (SELL) 44.7 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PTGX vs CRSP Buy Guide
PTGX CONSOLIDATION
64d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live PTGX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PTGX nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.